U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07186101) titled 'LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:' on Sept. 16.
Brief Summary: The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC).
Study participation will last approximately 114 weeks, including 104 weeks of treatment and may include up to 21 visits.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Ulcerative Colitis
Intervention:
DRUG: LY4268989
Administered PO
DR...